A Long-Term Follow-Up Study of Participants With Sickle Cell Disease or Transfusion Dependent β-Thalassemia Who Received EDIT-301
← catalyst calendarNCT06363760 · readout ≤ 5,126 d
Sponsored by Editas Medicine, Inc. (industry) · EDIT — their whole pipeline →.
Phase
—
Status
Enrolling by invitation
Study type
Observational
Enrollment
54estimated
Sites
18
Countries
Canada, United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-06-17 | actual | When the study began enrolling |
| Primary completion | Aug 2040 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Aug 2040 | estimated | The whole study's end, after follow-up |
| First posted | 2024-04-12 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-04-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Conditions
- Sickle Cell Disease
- Transfusion-dependent Beta-Thalassemia
- Hemoglobinopathies
Intervention
- Other: Safety and efficacy assessments
Primary outcomes
what the primary-completion date above is the date OFAdverse events of special interest (AESI)
measured up to 15 years post EDIT-301 infusion
Adverse events of interest (AEI)
measured up to 15 years post EDIT-301 infusion
All-cause mortality
measured up to 15 years post EDIT-301 infusion
Adverse events (AEs) related to EDIT-301
measured up to 15 years post EDIT-301 infusion
Serious adverse events (SAEs)
measured up to 15 years post EDIT-301 infusion
Permalink · EDIT's whole pipeline · Catalyst calendar · Every registered study · What changed